ESC 365 - SGLT2i in ESC 2021 HF management guideline - clinical implication.

ESC Premium Access

SGLT2i in ESC 2021 HF management guideline - clinical implication.

Session: Evolving role of SGLT2i in HFrEF management

Topic: Pharmacotherapy

Speaker: Doctor J. Kang (Seoul, KR)

Sponsored by AstraZeneca

Event: ESC Asia with APSC & AFC 2021

Congress Session

About the speaker

Doctor Jeehoon Kang

Seoul National University, Seoul (Korea (Republic of))

1 presentation

0 follower

3 more presentations in this session

Welcome and introduction.

Speaker: Professor C. Lam (Singapore, SG)

Emerging evidence for SGLT2i in HFrEF patients.

Speaker: Doctor P. Kumar Sahoo (Bhubaneswar, IN)

Discussion and live Q&A.

Access the full session

Evolving role of SGLT2i in HFrEF management

Speakers: Doctor J. Kang, Professor C. Lam, Doctor P. Kumar Sahoo

About the event

ESC Asia with APSC & AFC 2021

2 December - 4 December 2021

Sessions Presentations

Congress

Related content

ESC Premium Access

Ticagrelor implementation in PCI-treated ACS patients

27 August 2021

ESC Premium Access

TWILIGHT-Stent: Ticagrelor Monotherapy According to Stent Type

27 August 2021

ESC Premium Access

Benefits of SGLT2-1/2 Inhibition on Heart Failure, Ischemic, and Kidney Endpoints

27 August 2021

This platform is supported by